Mounjaro
tirzepatide · Eli Lilly
Form
Injectable pen (subcutaneous)
Frequency
Once weekly
Available Doses
FDA Approval Date
May 13, 2022
Mechanism
Dual GLP-1 + GIP receptor agonist
Manufacturer
Eli Lilly
Cost
Self-Pay
$499/mo flat (all doses) via LillyDirect
With Savings Card
$25/mo for commercially insured patients
List Price
~$1,086/mo
Same molecule as Zepbound. Widely covered by insurance for T2D.
Side Effects
| Side Effect | Rate | Source |
|---|---|---|
| Nausea | ~18-28% | SURPASS trials (dose-dependent) |
| Diarrhea | ~15-23% | SURPASS trials (dose-dependent) |
| Decreased appetite | ~10-20% | SURPASS trials |
| Vomiting | ~5-12% | SURPASS trials (dose-dependent) |
| Constipation | ~6-11% | SURPASS trials |
| Injection site reactions | ~3% | SURPASS trials |
Source: SURPASS Clinical Trial Program (SURPASS 1-5)
Weight Loss Results
SURPASS-1
~9.5%
40 weeks · Multiple analyses
In type 2 diabetes patients (lower weight loss than in obesity populations due to patient profile).
How It Works
Mounjaro works identically to Zepbound — it activates both GLP-1 and GIP receptors. In diabetes patients, this dual action improves insulin secretion, reduces glucagon, slows gastric emptying, and promotes weight loss. The A1C reduction with tirzepatide is among the most potent available.
Mechanism: Mounjaro is the same molecule as Zepbound (tirzepatide). The difference is the FDA indication: Mounjaro is approved for type 2 diabetes, while Zepbound is approved for weight management. The drug itself is identical.
Who It's For
Indication
Type 2 diabetes mellitus (widely used off-label for weight loss)
Adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Also widely prescribed off-label for weight management. Same molecule as Zepbound but with different insurance coverage (typically better coverage for T2D).
Food & Water Restrictions
✅ No Restrictions
This medication can be taken at any time of day, with or without food and water.
Switching Guides
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Clinical trial data referenced comes from published studies and FDA prescribing information. Side effect rates are from specific clinical trials and may not reflect real-world experience. Always consult your healthcare provider before starting, stopping, or switching any medication.